BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
Status:
Recruiting
Trial end date:
2022-07-04
Target enrollment:
Participant gender:
Summary
Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that
transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation
and subsequent lysis of tumor cells.
The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab
administered after R-CHOP debulking therapy in patients with Richter Syndrome (RS) of diffuse
large B-cell lymphoma (DLBCL) histology.
The investigators hypothesize that 8-week blinatumomab induction therapy leads to Complete
Response (CR) rate improvement (revised Cheson criteria) from a baseline of 7percent as
observed in the prospective study evaluating R-CHOP.